•  
  •  
 

Corresponding Author

Hossam Aldein Atia Masamer

Document Type

Original Article

Abstract

Background: In 2020, the abbreviation "metabolic dysfunction-associated fatty liver diseases" (MAFLD) was employed to denote hepatic steatosis associated with systemic metabolic dysfunction.

Aim and objectives: To evaluate the diagnostic and clinical use of the width of red cell distribution to platelet ratio as a noninvasive surrogate marker for liver stiffness in fatty liver diseases linked to metabolic dysfunction.

Patients and methods: The current cross-sectional study was carried out on 100 MAFLD patients presented in the MAFLD outpatients' clinic, National Hepatology and Tropical Medicine Research Institute (NHTMRI) incorporation with El-Hussein University hospital-internal medicine department from March to August 2023.

Results: The highest mean value of Red cell distribution width to platelet ratio (RPR) was higher in Fibrosis F4 (0.107±0.016), followed by Fibrosis F3 (0.098±0.013), then Fibrosis F2 (0.070±0.025), with the most negligible value recorded in F1 (0.044±0.012). RPR can be a noninvasive diagnosis indicator for predicting extensive fibrosis in patients with NAFLD.

Conclusion: RPR is a straightforward and readily accessible measure for estimating the severity of MAFLD disease. When predicting MAFLD, the RPR index outperforms FAST, FIB-4, and APRI due to its greater AUC. In patients with MAFLD, RPR can be employed as a noninvasive diagnosis marker to forecast severe fibrosis.

Keywords

Red Distribution Width; Platelet ratio; hepatic fibrosis; metabolic dysfunction

Subject Area

Internal Medicine

Share

COinS